Journal of Hepatology
Volume 53, Issue 2 , Pages 362-371 , August 2010

Hemostasis and thrombosis in patients with liver disease: The ups and downs

  • Ton Lisman

      Affiliations

    • Section Hepatobiliairy Surgery and Liver Transplantation, The Netherlands
    • Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Surgical Research Laboratory, BA 44, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands. Tel.: +31 50 3619028; fax: +31 50 363 2796.
    • ,
  • Stephen H. Caldwell

      Affiliations

    • Division of GI/Hepatology, Department of Internal Medicine, University of Virginia, Charlottesville, VA, USA
    • ,
  • Andrew K. Burroughs

      Affiliations

    • The Sheila Sherlock Hepatobiliary-Pancreatic and Liver Unit, Royal Free Hospital, London, United Kingdom
    • ,
  • Patrick G. Northup

      Affiliations

    • Division of GI/Hepatology, Department of Internal Medicine, University of Virginia, Charlottesville, VA, USA
    • ,
  • Marco Senzolo

      Affiliations

    • Gastroenterology, Department of Surgical and Gastroenterological Sciences, University Hospital of Padua, Italy
    • ,
  • R. Todd Stravitz

      Affiliations

    • Section of Hepatology, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • Armando Tripodi

      Affiliations

    • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, University Medical School and IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy
    • ,
  • James F. Trotter

      Affiliations

    • Baylor University Medical Center, Dallas, TX, USA
    • ,
  • Dominique-Charles Valla

      Affiliations

    • Centre de Référence des Maladies Vasculaires du Foie, AP-HP, Hôpital Beaujon, Service d’Hépatologie, Clichy, France
    • ,
  • Robert J. Porte

      Affiliations

    • Section Hepatobiliairy Surgery and Liver Transplantation, The Netherlands
    • ,
  • Coagulation in Liver Disease Study Group

Received 11 January 2010 ,Revised 28 January 2010 ,Accepted 29 January 2010.

References 

  1. Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002;37:280–287
  2. Lisman T, Caldwell SH, Leebeek FW, Porte RJ. Is chronic liver disease associated with a bleeding diathesis?. J Thromb Haemost. 2006;4:2059–2060
  3. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol. 2007;46:727–733
  4. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost. 2008;6:2–9
  5. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250–258
  6. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039–1046
  7. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61
  8. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735
  9. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454:345–359
  10. Senzolo M, Cholongitas E, Thalheimer U, Riddell A, Agarwal S, Mallett S, et al. Heparin-like effect in liver disease and liver transplantation. Clin Liver Dis. 2009;13:43–53
  11. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–558
  12. Tripodi A, Primignani M, Chantarangkul V, Dell’Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs. anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009;137:2105–2111
  13. Lisman T, Bakhtiari K, Pereboom ITA, Hendriks HGD, Meijers J, Porte R. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol. 2010;52:355–361
  14. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131–139
  15. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13:511–531
  16. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354–1358
  17. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men – role of the metabolic syndrome. Thromb Haemost. 1996;76:69–73
  18. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–480
  19. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res. 2008;5:138–144
  20. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11:950–956
  21. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13:95–107
  22. Kerr R, Newsome P, Germain L, Thomson E, Dawson P, Stirling D, et al. Effects of acute liver injury on blood coagulation. J Thromb Haemost. 2003;1:754–759
  23. Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology. 1993;18:1350–1356
  24. Warnaar N, Lisman T, Porte RJ. The two tales of coagulation in liver transplantation. Curr Opin Organ Transplant. 2008;13:298–303
  25. Lisman T, Caldwell SH, Leebeek FWG, Porte RJ. Hemostasis in chronic liver disease – Is chronic liver disease associated with a bleeding diathesis?. J Thromb Haemost. 2006;4:2059–2060
  26. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost. 2006;4:721–723
  27. de Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ. Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. Dig Surg. 2005;22:265–275
  28. Massicotte L, Beaulieu D, Thibeault L, Roy JD, Marleau D, Lapointe R, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation. 2008;85:956–962
  29. Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transplant. 2006;12:117–123
  30. Castaneda B, Debernardi-Venon W, Bandi JC, Andreu V, Perez-Del-Pulgar S, Moitinho E, et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology. 2000;31:581–586
  31. Vieira da Rocha EC, D’Amico EA, Caldwell SH, Flores da Rocha TR, Silva SoaresE, CS Dos, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol. 2009;7:988–993
  32. Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000;118:905–911
  33. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45:1413–1425
  34. Sharma M, Yong C, Majure D, Zellner C, Roberts JP, Bass NM, et al. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. Am J Cardiol. 2009;103:742–746
  35. De Gottardi A, Thevenot T, Spahr L, Morard I, Bresson-Hadni S, Torres F, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7:906–909
  36. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–1044
  37. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology. 1986;6:79–86
  38. Anantharaju A, Mehta K, Mindikoglu AL, Van Thiel DH. Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci. 2003;48:1414–1424
  39. Park DH, Kim MH, Lee SK, Lee SS, Choi JS, Song MH, et al. Endoscopic sphincterotomy vs. endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc. 2004;60:180–185
  40. Sindet-Pedersen S. Haemostasis in oral surgery – the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system. Dan Med Bull. 1991;38:427–443
  41. Auzinger G, O’Callaghan GP, Bernal W, Sizer E, Wendon JA. Percutaneous tracheostomy in patients with severe liver disease and a high incidence of refractory coagulopathy: a prospective trial. Crit Care. 2007;11:R110
  42. Agarwal B, Shaw S, Hari MS, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different?. J Hepatol. 2009;51:504–509
  43. Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis. 2009;13:73–85
  44. Gronbaek H, Johnsen SP, Jepsen P, Gislum M, Vilstrup H, Liver Tage-JensenU, et al. BMC Gastroenterol. 2008;8:16
  45. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35:2498–2508
  46. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345:669–681
  47. Violi F, Leo R, Basili S, Ferro D, Cordova C, Balsano F. Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica. 1994;79:61–65
  48. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992;15:672–676
  49. Tacke F, Fiedler K, Trautwein C. A simple clinical score predicts high risk for upper gastrointestinal hemorrhages from varices in patients with chronic liver disease. Scand J Gastroenterol. 2007;42:374–382
  50. Siringo S, McCormick PA, Mistry P, Kaye G, McIntyre N, Burroughs AK. Prognostic significance of the white nipple sign in variceal bleeding. Gastrointest Endosc. 1991;37:51–55
  51. Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology. 2003;38:1378–1383
  52. Castaneda B, Morales J, Lionetti R, Moitinho E, Andreu V, Perez-Del-Pulgar S, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology. 2001;33:821–825
  53. Colomo A, Hernanzez-Gea V, Madoz P, Carles A, Alvarez-Urturi C, Poca M, et al. Hymodynamic changes and transfusion strategies in cirrhotic patients with acute variceal bleeding. Hepatology. 2009;50:403Aa
  54. Boyer JL, Chatterjee C, Iber FL, Basu AK. Effect of plasma-volume expansion on portal hypertension. N Engl J Med. 1966;275:750–755
  55. Pereboom ITA, de Boer MT, Haagsma EB, Hendriks HGD, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg. 2009;108:1083–1091
  56. de Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg. 2008;106:32–44
  57. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood. 2008;112:2617–2626
  58. Shah NL, Caldwell SH, Berg CL. The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue?. Clin Liver Dis. 2009;13:87–93
  59. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut. 1975;16:617–620
  60. Munoz SJ, Rajender Reddy K, Lee W. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care. 2008;9:103–107
  61. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33:41–48
  62. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207–1212
  63. Vivas S, Rodriguez M, Palacio MA, Linares A, Alonso JL, Rodrigo L. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci. 2001;46:2752–2757
  64. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut. 1998;43:267–271
  65. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol. 2002;37:463–470
  66. Senzolo M, Coppell J, Cholongitas E, Riddell A, Triantos CK, Perry D, et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis. 2007;18:227–236
  67. Jun CH, Park CH, Lee WS, Joo YE, Kim HS, Choi SK, et al. Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. J Korean Med Sci. 2006;21:883–890
  68. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39:746–753
  69. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med. 2003;139:186–193
  70. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci. 2008;53:3012–3017
  71. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96–101
  72. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006;101:1524–1528
  73. Garcia-Fuster MJ, Abdilla N, Fabia MJ, Fernandez C, Oliver V, Forner MJ. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig. 2008;100:259–262
  74. Warnaar N, Molenaar IQ, Colquhoun SD, Slooff MJ, Sherwani S, de Wolf AM, et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. J Thromb Haemost. 2008;6:297–302
  75. Melato M, Mucli E, Poldrugo F, Valente M, Zanconati F, Okuda K. Stroke-cirrhosis relationship: an autopsy study in a heavy drinking population. Ital J Gastroenterol. 1991;23:211–214
  76. Howell WL, MANION WC. The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: A review of 639 cases of cirrhosis of the liver from 17, 731 autopsies. Am Heart J. 1960;60:341–344
  77. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, et al. Cardiovascular disease in cirrhosis – a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol. 1999;94:655–662
  78. Britton KA, Gaziano JM, Sesso HD, Djousse L. Relation of alcohol consumption and coronary heart disease in hypertensive male physicians (from the Physicians’ Health Study). Am J Cardiol. 2009;104:932–935
  79. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991;338:464–468
  80. Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595–599
  81. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31:366–374
  82. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54:691–697
  83. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51:682–689
  84. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology. 1992;16:1195–1198
  85. Orloff MJ, Orloff MS, Orloff SL, Girard B. Portal vein thrombosis in cirrhosis with variceal hemorrhage. J Gastrointest Surg. 1997;1:123–130[Discussion]
  86. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40:736–741
  87. Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4, 200 patients. J Am Coll Surg. 2009;208:896–903
  88. Lisman T, Porte RJ. Hepatic artery thrombosis after liver transplantation: more than just a surgical complication?. Transplant Int. 2009;22:162–164
  89. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–1247
  90. MacPhee PJ, Dindzans VJ, Fung LS, Levy GA. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology. 1985;5:649–660
  91. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology. 2004;39:365–375
  92. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009;119:2550–2563
  93. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, et al. Coagulation and fibrosis in chronic liver disease. Gut. 2008;57:1722–1727
  94. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost. 2008;6:1336–1343
  95. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003;52:1206–1210
  96. Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46:286–294
  97. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest. 2004;34:482–489
  98. Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol. 2009;51:931–938
  99. Sullivan CM, Hickman IJ, Flight S, Campbell C, Crawford DH, Masci PP, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:331–338
  100. Westerkamp AC, Lisman T, Porte RJ. How to minimize blood loss during liver surgery in patients with cirrhosis. HPB (Oxford). 2009;11:453–458
  101. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell’Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44:440–445
  102. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98:1391–1394
  103. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930–1937
  104. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269–275
  105. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplant. 2005;11:973–979
  106. Planinsic RM, van der MJ, Testa G, Grande L, Candela A, Porte RJ, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplant. 2005;11:895–900
  107. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47:1604–1614
  108. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298
  109. Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG. Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis. 1995;25:241–247
  110. Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed). 1985;291:1377–1381
  111. de Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology. 1993;18:1102–1107
  112. Pivalizza EG, Warters RD, Gebhard R. Desmopressin before liver transplantation. Can J Anaesth. 2003;50:748–749
  113. Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth. 2003;50:14–20
  114. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet. 2000;355:1303–1309
  115. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996;85:1043–1048
  116. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95:S13–S17
  117. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–2236
  118. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?. HPB (Oxford). 2009;11:459–464
  119. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant. 2007;7:1624–1628
  120. Lisman T, van Leeuwen Y, Adelmeijer J, Pereboom IT, Haagsma EB, van den Berg AP, et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int. 2008;28:1344–1351
  121. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology. 2008;47:1384–1393
  122. Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant. 2009;9:746–757
  123. Gunsar F, Rolando N, Pastacaldi S, Patch D, Raimondo ML, Davidson B, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transplant. 2003;9:605–611
  124. Lisman T, Porte RJ. Antiplatelet medication after liver transplantation: does it affect outcome?. Liver Transplant. 2007;13:644–646
  125. Vivarelli M, La BG, Cucchetti A, Lauro A, Del GM, Ravaioli M, et al. Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?. Liver Transplant. 2007;13:651–654
  126. Sieders E, Peeters PM, TenVergert EM, de Jong KP, Porte RJ, Zwaveling JH, et al. Early vascular complications after pediatric liver transplantation. Liver Transplant. 2000;6:326–332
  127. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583–1591

PII: S0168-8278(10)00382-X

doi: 10.1016/j.jhep.2010.01.042

Journal of Hepatology
Volume 53, Issue 2 , Pages 362-371 , August 2010

Article Tools

* Image Usage & Resolution